Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis

doi:10.4251/wjgo.v15.i8.1451

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3499)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

100

WORD

116

HTML

2162

Figures (1-1)

213

Tables (1-2)

211

Sum=2802

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

130

Download

435

Sum=565

Aug 15, 2023 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Aug 15, 2023; 15(8): 1451-1460
Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1451

Table 1 Anthropometric, biochemical, and histological features of the overall population included (176 patients)

Classification	Features
Sex, n (%)	Female: 142 (80.7)
Age (median)	64 yr (IQR: 53–71)
APCA positivity, n (%)	147 (83.5)
Gastrin	668 pg/mL (IQR: 340–1200)
Chromogranin A (median)	146 ng/mL (IQR: 106–219)
ECL hyperplasia, n (%)	Absent: 60 (34.1)
Gastric mucosa atrophy, n (%)	OLGA
	0: 58 (32.9)
	I: 38 (21.6)
	II: 64 (36.4)
	III: 13 (7.4)
	IV: 3 (1.7)
Gastric mucosa intestinal metaplasia, n (%)	OLGIM
	0: 42 (23.9)
	I: 63 (35.8)
	II: 61 (34.7)
	III: 5 (2.8)
	IV: 5 (2.8)

BMI: Body mass index; APCA: Anti-parietal cell antibodies; ECL: Enterochromaffin-like cells; OLGA: Operative Link for Gastritis Assessment; OLGIM: Operative Link on Intestinal Metaplasia Assessment.

Citation: Massironi S, Gallo C, Elvevi A, Stegagnini M, Coltro LA, Invernizzi P. Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis. World J Gastrointest Oncol 2023; 15(8): 1451-1460
URL: https://www.wjgnet.com/1948-5204/full/v15/i8/1451.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i8.1451